191 results on '"Perera, Yasser"'
Search Results
2. CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling
3. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
4. On the gene expression landscape of cancer
5. Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2
6. Missing and spurious interaction in additive, multiplicative and odds ratio models
7. Positive effects of Phycocyanobilin on gene expression in glutamate-induced excitotoxicity in SH-SY5Y cells and animal models of multiple sclerosis and cerebral ischemia
8. Genetic interactions from first principles
9. Evaluation of Cell-Penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination
10. A Nasal Vaccine Candidate, Containing Three Antigenic Regions from SARS-CoV-2, to Induce a Broader Response
11. The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality
12. Impact of germline susceptibility variants in cancer genetic studies
13. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome
14. “Phosphoproteomic quantification based on phosphopeptide intensity or occupancy? An evaluation based on casein kinase 2 downstream effects”
15. Cloning, expression, purification and characterization of the recombinant nucleocapsid protein from SARS-CoV-2 and its combination with a CpG ODN-39M
16. On Casein Kinase-2 (CK2) deregulation in NSCLC: an enzyme subunit-centered approach
17. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
18. CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy
19. Supplementary Table S1 from Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
20. Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells
21. On the gene expression landscape of cancer
22. Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors
23. Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma
24. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
25. Reajuste de densidad aparente y retención de carbono: Modelos idoneos para arenas cubanas
26. Additional file 1 of Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
27. Broad Humoral Immunity Generated in Mice by a Formulation Composed by Two Antigens From Delta Variant of SARS-CoV-2
28. CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
29. The Nucleocapsid Protein Of SARS-CoV-2, Combined With ODN-39M, Is A Potential Component For An Intranasal Bivalent Pancorona Vaccine
30. Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis
31. Gel electrophoresis/electroelution sorting fractionator combined with filter‐aided sample preparation for deep proteomic analysis
32. CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition
33. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
34. CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model.
35. CIGB-300 synthetic peptide, an antagonist of CK2 kinase activity, as a treatment for Covid-19. A computational biology approach
36. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
37. Evaluation of Cell-penetrating Peptides as Mucosal Immune Enhancers for Nasal Vaccination
38. Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection
39. Mining B23/NPM1 public genomic data: Is B23/NPM1 a suitable cancer target beyond Acute Myeloid Leukemia?
40. Perera et al. Peptides Meeting-2019
41. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research
42. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
43. Gel Electrophoresis/Electroelution Sorting Fractionator combined with Filter Aided Sample preparation (FASP) for deep proteomic analysis
44. Análisis fosfoproteómico de dos subtipos de LMA revela patrones comunes y divergentes en respuesta a la inhibición de la proteína quinasa CK2
45. GENETIC INTERACTIONS FROM FIRST PRINCIPLES
46. Principal Component Analysis of RNA-seq Data Unveils a Novel Prostate Cancer-Associated Gene Expression Signature
47. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
48. Positive Effects of Phycocyanobilin on Gene Expression in Glutamate-Induced Excitotoxicity in SH-SY5Y Cells and Animal Models of Neurodegenerative Diseases
49. CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo
50. Principal component analysis of RNA-seq data unveils a novel prostate cancer-associated gene expression signature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.